DexCom, Inc. (DXCM)
After hours:
| Previous Close | 127.37 |
| Open | 126.70 |
| Bid | 127.36 x 400 |
| Ask | 127.47 x 400 |
| Day's Range | 125.26 - 128.04 |
| 52 Week Range | 74.75 - 142.00 |
| Volume | |
| Avg. Volume | 2,784,795 |
| Market Cap | 50.657B |
| Beta (5Y Monthly) | 1.22 |
| PE Ratio (TTM) | 82.71 |
| EPS (TTM) | 1.54 |
| Earnings Date | Jul 25, 2024 - Jul 29, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 153.37 |
ZacksWhy DexCom (DXCM) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Simply Wall St.With EPS Growth And More, DexCom (NASDAQ:DXCM) Makes An Interesting Case
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Business WireDexcom Launches Innovative New Sensor as Groundbreaking Report Reveals Alarming Rates of Anxiety and Depression in Those With Type 2 Diabetes
LONDON, May 20, 2024--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM device that easily tracks real-time glucose readings to help improve diabetes management, and the Dexcom State of Type 2 Report. The report is a first-of-its-kind look at the Type 2 landscape today and examines the preferences and behaviours of those living with the condition, as well as their caretaker
